Galena Biopharma Takes Final Actions to Complete Spin-Off of RXi Pharmaceuticals Galena Biopharma, Inc. announced that it has initiated the final steps to complete the previously announced spin-off of RXi Pharmaceuticals Corporation, Galena’s wholly-owned subsidiary. [Galena Biopharma, Inc.] Press Release
TechColumbus Commits $500,000 to Fund Ohio State University Spinoff Nanofiber Solutions TechColumbus announced its commitment to invest $500,000 from its Pre-Seed Fund in Nanofiber Solutions LLC to advance innovations in cell culture technologies and regenerative medicine. [TechColumbus] Press Release
Argos Therapeutics Secures $25 million Series D Financing to Commence Phase III ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012 Argos Therapeutics Inc. announced that it has secured a $25 million Series D financing to support the commencement of its Phase III ADAPT study in patients with newly diagnosed, mRCC in mid-2012. [MarketWatch] Press Release SynGen Inc. Receives $5 million Equity Investment from Bay City Capital, LLC SynGen Inc. announced that it has completed a $5 million Series A preferred stock financing with Bay City Capital, LLC (BCC). Under the terms of the transaction, BCC will appoint two representatives to SynGen’s board of directors. [PR Newswire] Press Release MiRagen Therapeutics Secures $20 Million Series B Financing MiRagen Therapeutics, Inc. announced the completion of a $20 million Series B financing. The funding enables miRagen to advance the development of its compelling microRNA-based therapeutics pipeline. [MiRagen Therapeutics, Inc.] Press Release Pluristem Awarded a $3.1 Million Grant by Israeli Government Pluristem Therapeutics Inc. announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 11.8 million New Israeli Shekels (approximately $3.1 million) grant from the Office of the Chief Scientist within the Israeli Ministry of Industry, Trade and Labor. [Pluristem Therapeutics Inc.] Press Release TAP Biosystems’ Project to Develop a Cell Therapy for Corneal Surface Disease Receives Additional Funding for Pre-Clinical and First in Man Trials TAP Biosystems announced it has received further funding from the UK’s Technology Strategy Board. This will advance their project, developing a biomimetic cornea to treat corneal surface disease, into pre-clinical research and a safety trial in two patients. [TAP Biosystems] Press Release ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt’s Disease Patients in U.S. Trial Advanced Cell Technology, Inc. (ACT) announced that the DSMB have recently authorized the Company to move forward with enrollment and treatment of additional patients with Stargardt’s disease. [Advanced Cell Technology, Inc.] Press Release Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase II Trial of TSO in Crohn’s Disease Coronado Biosciences, Inc. announced that it received from Dr. Falk Pharma GmbH (Falk), its development partner, a recommendation from the independent data monitoring committee that conducted an interim analysis (blinded to Falk) of clinical data from the initial 120 patients to continue Falk’s Phase II clinical trial in Europe evaluating Trichuris suis ova (TSO) in Crohn’s disease. [Coronado Biosciences, Inc.] Press Release Second U-M Stem Cell Line Now Publicly Available to Help Researchers Find Treatments for Nerve Condition The University of Michigan (U-M)’s second human embryonic stem cell line has just been placed on the U.S. National Institutes of Health’s registry, making the cells available for federally-funded research. [University of Michigan Health System] Press Release Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells Bioo Scientific announced that it has launched the proprietary MyeloAim™ and NeuroAim™ Transduction Reagents which offer directed delivery of RNAi agents into myeloid cells (both in primary cells and in cell lines) or into neuronal cells (both in primary cells and in cell lines) respectfully. [Bioo Scientific Corp.] Press Release New CU-Boulder Facility to be Used to Tackle Challenges Ranging from Cancer and Tissue Engineering to New Biofuels A revolutionary research and teaching facility opening at the University of Colorado Boulder (CU-Boulder) will facilitate work on a wide swath of pressing societal challenges ranging from biomedical issues like cancer, heart disease and tissue engineering to the development of new biofuels. [University of Colorado Boulder] Press Release
New Director, Associate Director at McGowan Institute for Regenerative Medicine William R. Wagner, Ph.D. has been named director of the McGowan Institute for Regenerative Medicine, a joint effort of Pitt and UPMC, effective immediately. Rocky S. Tuan, Ph.D. has been named associate director. [University of Pittsburgh Schools of the Health Sciences] Press Release |